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Objective: Very few cost-utility analyses have either evaluated direct-acting antivirals (DAAs) on hepatitis C virus (HCV)
genotype 6 patients or undertaken societal perspective. Recently, DAAs have been introduced into the Vietnamese health
insurance drug list for chronic hepatitis C (CHC) treatment without empirical cost-effectiveness evidence. This study was
conducted to generate these data on DAAs among CHC patients with genotypes 1 and 6 in Vietnam.
Methods: A hybrid decision-tree and Markov model was employed to compare costs and quality-adjusted life-years (QALYs) of
available DAAs, including (1) sofosbuvir/ledipasvir, (2) sofosbuvir/velpatasvir, and (3) sofosbuvir plus daclatasvir, with
pegylated-interferon plus ribavirin (PR). Primary data collection was conducted in Vietnam to identify costs and utility
values. Incremental cost-effectiveness ratios were estimated from societal and payer perspectives. Uncertainty and
scenario analyses and value of information analyses were performed.
Results: All DAAs were cost-saving as compared with PR in CHC patients with genotypes 1 and 6 in Vietnam, and sofosbuvir/
velpatasvir was the most cost-saving regimen, from both societal and payer perspectives. From the societal perspective, DAAs
were associated with the increment of quality-adjusted life-years by 1.33 to 1.35 and decrement of costs by $6519 to $7246.
Uncertainty and scenario analyses confirmed the robustness of base-case results, whereas the value of information analyses
suggested the need for further research on relative treatment efficacies among DAA regimens.
Conclusions: Allocating resources for DAA treatment for HCV genotype 1 and 6 is surely a rewarding public health investment
in Vietnam. It is recommended that the government rapidly scale up treatment and enable financial accessibility for HCV
patients.
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In Vietnam, an estimated 1%-2% of the total population is
infected with hepatitis C virus (HCV)1-5 and there are 6 new HCV
infections per 100 000 persons annually.6 In addition, Vietnam is
also found to have the unique HCV genotype 6 as the most
prevalent genotype, followed by HCV genotype 1, which together
account for more than 85% of HCV infections.7-11 It should be
noted that genotype 6, which is mainly found in Southeast Asia,
and only accounts for 2% of HCV infections in the world, is rela-
tively restricted in geographical extent.12,13ss correspondence to: Usa Chaikledkaew, PhD, Social and Administrative Ph
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doi.org/10.1016/j.jval.2020.03.018Since 2019, the Ministry of Health has implemented a new
health insurance drug list, where direct-acting antiviral (DAA)
regimens have been introduced for the first time. Three regimens
were included: (1) sofosbuvir/ledipasvir (SOF/LDV), (2) sofosbuvir/
velpatasvir (SOF/VEL), and (3) sofosbuvir plus daclatasvir
(SOF1DCV), while also retaining the old standard of HCV treat-
ment, pegylated-interferon plus ribavirin (PR).14 Nevertheless,
there has been no empirical evidence on the cost-effectiveness of
the newly included DAA regimens in the Vietnamese population.
Although there have already been several cost-utility analyses
(CUAs) of DAA regimens conducted, very few have evaluated DAAarmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol
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2 VALUE IN HEALTH - 2020regimens on HCV genotype 6, been conducted in low- and middle-
income countries (LMICs), or undertook a societal perspective,
according to the results of recently published systematic reviews
on CUAs of DAA regimens.15-18 This has posed a significant gap in
knowledge on the adaptability of the new DAAs. Therefore, this
CUA was conducted on an HCV population genotype 1 and 6 in
Vietnam, from both societal and payer perspectives. The cost-
effective evidence generated by this study may inform policy
makers in revising the drug list in the coming years and revising
the HCV treatment guidelines. Moreover, this study may
contribute to the global knowledge on the cost-effectiveness of
DAA regimens, as being among the first CUAs of DAA regimens
that considered HCV genotype 6 patients in an LMIC using a so-
cietal perspective.Methods
Target Population
The model simulated cohorts of patients infected with HCV
genotype 1 and 6 in Vietnam because these 2 genotypes are the
most prevalent.7-11 The mean age of the HCV patients was
assumed to be 50 years old, based on the results from recent
surveys in Vietnam.9-11,19,20 The patients had no comorbidity and
were at either non-cirrhotic chronic hepatitis C (CHC) or
compensated cirrhosis (CC) health states—the 2 heath states that
are eligible for HCV antiviral treatment in Vietnam.21,22
Model Structure
A hybrid of decision-tree and Markov models adapted from
Kapol et al23 was applied, which was validated by clinical experts
in Vietnam’s National Hospital of Tropical Diseases.
Patients entered a decision tree at the initiation of treatment
and were chosen to receive either DAA regimens or PR. Upon
completion of each regimen, patients could move to 1 of corre-
sponding 4 health states based on their status of sustained viro-
logic response (SVR)—the indication of successful treatment. CHC
and CC patients who achieved SVR were assumed to be cured, but
CC patients could still progress to hepatocellular carcinoma
(HCC),24-27 although at a slower rate, and patients who failed to
achieve SVR would continue to progress over time. Therefore, allFigure 1. The hybrid decision-tree and discrete-time, state-transition
CC indicates compensated cirrhosis; CHC, non-cirrhotic chronic hepatitis C; DC,
LDV, ledipasvir; LRD, liver-related death; PR, pegylated-interferon plus ribaviri
velpatasvir.patients, except those who achieved SVR from CHC, moved to a
discrete-time state-transition Markov model for natural disease
progression (Fig. 1).
The Markov model was based on the natural history of hepa-
titis C, and the classification of health states was in line with the
current treatment guidelines in Vietnam.22 There were 6 mutually
exclusive health states, including an SVR state achieved after
successful treatment of CC, 4 disease states (ie, CHC, CC, decom-
pensated cirrhosis [DC], and HCC), and a dead state, which was
liver-related death (LRD). The age-specific probabilities of all-
cause mortality were applied to all health states, whereas only
patients with DC and HCC would die from liver-related mortality.
The model simulation ended when all patients in the cohort died
(ie, reached 100 years old according to the latest life table of
Vietnam).28 We assumed that patients who failed treatment were
not re-treated, and all patients completely complied with the
treatment.
Costs and health outcomes were estimated in a lifetime period
with 1-year cycle length. A within-cycle correction method, the
Simpson’s one-third rule correction method,29 was applied, as
suggested by Elbasha and Chhatwal.30 An annual discount rate of
3% was used for both costs and outcomes, as suggested by the
World Health Organization.31 Costs were converted to Vietnamese
Dong in the year 2019 using Vietnam’s consumer price index,32
then converted to US dollars using the exchange rate of $1.00 =
23143 Vietnamese Dong.33 The cost-effectiveness threshold
of 1 gross domestic product (GDP) per capita of Vietnam ($2389)
was used.34 The model was designed and run in Microsoft Office
Excel.
The CUA from a societal perspective estimated cost compo-
nents such as direct medical and direct non-medical costs,
including time cost associated with the treatment of patients and
their caregivers (ie, informal care). The indirect costs (ie, morbidiy
cost and mortality cost) were excluded to avoid a double-counting
issue in the CUA.35,36 Meanwhile, the analysis from a payer
perspective only estimated direct medical cost covered by the
payer in Vietnam—the Vietnam Social Security.
Interventions and Comparator
All DAA regimens in the current Vietnamese health insurance
drug list,14 including SOF/LDV, SOF1DCV, and SOF/VEL, wereMarkov model.
decompensated cirrhosis; DCV, daclatasvir; HCC, hepatocellular carcinoma;
n; SOF, sofosbuvir; SVR, sustained virologic response; RBV, ribavirin; VEL,
-- 3compared with the old standard of HCV treatment (ie, PR). Rec-
ommendations of treatment regimens and durations were based
on Vietnam’s current treatment guidelines.21,22
Model Parameters
The model considered the following input parameters, classi-
fied into 4 major groups: transition probabilities, treatment effi-
cacy, costs, and utilities (Table 1).
Transition probabilities
The disease-related transition probabilities were obtained from
Japan owing to the unavailability of data in Vietnam. Among Asian
countries, Japan was found to have the most comprehensive set of
transition probabilities estimated from their own popula-
tion.26,27,37,38 To test the validity of these transition probabilities,
cross-model validations were performed to compare the long-
term disease progression predicted by this model against other
published models. The age-specific probabilities of all-causes
mortality were derived from the latest life table of Vietnam pub-
lished by the Vietnam General Statistics Office in 2016.28
Treatment efficacy
Treatment efficacy of HCV antivirals was measured by the rate
of SVR at the 12th week after stopping antivirals (SVR12). For HCV
genotype 1, a systematic search of existing meta-analyses on the
efficacy of DAA regimens in genotype 1 was performed, which
identified 7 relevant meta-analyses.39-45 Individual trials were
extracted from these meta-analyses by DAA regimens. For regi-
mens that had only 1 meta-analysis (such as SOF/VEL), we used
the result of that meta-analysis; meanwhile, for regimens that had
more than 1 meta-analysis (such as SOF/LDV and SOF1DCV), we
performed a new pooling and used our pooled result. Regarding
HCV genotype 6, we conducted a meta-analysis to pool SVR12
from existing trials on DAA regimens in genotype 6.46 The treat-
ment efficacy of PR was obtained from a published meta-
analysis.47
Costs
Direct medical, direct non-medical, and time costs associated
with treatment were obtained from primary data collection in
Vietnam’s 2 central-level hospitals, Bach Mai Hospital and the
National Hospital of Tropical Diseases, in 2019. Ethics approval for
the study was granted by the Institutional Review Board of the
Hanoi University of Public Health, Vietnam, on July 24, 2018.48
Direct medical costs included costs of antivirals (SOF/LDV, SOF/
VEL, SOF1DCV, PR), treatment monitoring (HCV RNA test, fibro-
scan, ultrasound, genotyping, and other blood tests), and palliative
care for patients who failed to achieve SVR12. Direct medical costs
were estimated by applying a cost-at-charge approach. In costing,
the usual practice is to assume that market price was a reasonable
approximation of monetary cost.49-51 Direct medical costs were
collected retrospectively from patient records.
Direct non-medical costs included travel, accommodation,
meals, and other relevant non-medical costs (eg, buying personal
belongings for patients during hospitalization) of patients and
their caregivers. These costs were estimated by prospectively
interviewing patients or their caregivers.
Time costs were the costs of time loss associated with the
treatment, which were borne by patients (or their caregivers) in
seeking care and waiting and receiving care at hospital (or aiding
patients to do so). These time costs were valuated using the hu-
man capital approach35 (ie, multiplying the days lost by the
average daily wage). The number of days lost were prospectively
collected from interviewing patients or their caregivers.Utilities
The health outcome of choice was quality-adjusted life-years
(QALYs), which is the multiplication of life years (LYs) by utility
score. The utility of each health state was obtained from primary
data collection using the EQ-5D-5L questionnaire52,53 in the
aforementioned hospitals in 2019, and the EQ-5D-5L value set of
Vietnam was applied.54 Permission from the EuroQoL group was
granted for using the Vietnamese version of the questionnaire.
Ethics approval for the study was granted by the Institutional
Review Board of the Hanoi University of Public Health.48 Each
patient participated in 1 interview, conducted when the patient
was at the hospital for either outpatient or inpatient care due to
their HCV-related complications.
Result Presentation
Total costs, LYs, and QALYs for each treatment were estimated
in a lifetime period. In addition, lifetime cumulative incidence of
HCV-related complications was calculated by cumulatively adding
up the number of HCV-related complications from the first cycle
to the last cycle in the model.
To estimate the cost-effectiveness of each regimen compared
with PR, an incremental cost-effectiveness ratio, calculated by an
incremental cost divided by an incremental LY or QALY, was esti-
mated and compared with the cost-effectiveness threshold of 1
GDP per capita of Vietnam per QALY gained. Furthermore, the
corresponding net monetary benefit (NMB) of all 3 DAA regimens
was compared in order to rank their cost-effectiveness.
Uncertainty Analysis
Parameter uncertainty
To test the robustness of the base-case results, a deterministic
1-way sensitivity analysis was performed by stochastically varying
1 parameter at a time between its lower and upper limits, and the
corresponding change of NMB was captured and shown graphi-
cally as a tornado diagram. Key parameters varied including dis-
count rates (±3%), transition probabilities (±20%), treatment
efficacies (because the SVR12s of DAAs were relatively high, their
range for variation was purposely set between –20% and 100%),
costs (±20%), utilities (95% confidence interval [CI]), and epide-
miology parameters (±20%).
In addition, to assess the impact of parameter uncertainty on
the results, probabilistic sensitivity analyses were conducted by
stochastically varying all key parameters simultaneously within
their probability distribution. The Monte Carlo simulation was run
in 1000 iterations, then shown graphically as a cost-effectiveness
plane and a cost-effectiveness acceptability curve.
Scenario analysis
In the base-case CUA, the government’s co-payment rate for
DAA regimens was set at 50%, according to current regulation.14 To
examine the generalizability of the model, scenarios of different
government’s copayment rates for DAA regimens (50%, 70%, 90%,
and 100%) were also explored.
Value of Information Analysis
The study performed the value of information analysis in terms
of total expected value of perfect information (EVPI) and expected
value of partial perfect information (EVPPI) in order to estimate
the expected value of further information to resolve the current
uncertainty and to identify which type of information would be
the most worthwhile.
The time horizon for estimating EVPI for population was set at
5 years, which was assumed to be the lifespan of these DAA reg-
imens. The annual affected population was calculated by
Table 1. Input parameters used in the model.
Input parameters Mean Standard error Distribution Source
Transition probabilities
From To
CHC CC 0.019 0.005 Beta 38
CC DC 0.056 0.014 Beta 37
HCC 0.056 0.014 Beta 37
DC HCC 0.056 0.014 Beta 37
LRD 0.151 0.038 Beta 37
HCC LRD (year 1) 0.118 0.030 Beta 38
LRD (from year 2) 0.222 0.056 Beta 38
SVR (CC) HCC 0.018 0.005 Beta 27
Treatment efficacy (SVR12)
Genotype 1
SOF/LDV 0.980 0.008 Beta Meta-analysis
SOF/VEL 0.980 0.005 Beta Meta-analysis
SOF1DCV 0.990 0.020 Beta Meta-analysis
PegIFN1RBV 0.625 0.096 Beta 47
Genotype 6
SOF/LDV 0.992 0.008 Beta 46
SOF/VEL 1.000 - Beta 46
SOF1DCV 0.990 0.020 Beta 46
PegIFN1RBV 0.802 0.027 Beta 47
Costs (US dollars, 2019)
Direct medical cost
Drug cost
SOF/LDV (12-week) 1,384.4 276.9 gamma Primary data
SOF/VEL (12-week) 1,739.7 347.9 gamma Primary data
SOF1DCV (12-week) 1,733.0 346.6 gamma Primary data
PegIFN (per week) 114.5 22.9 gamma Primary data
RBV (per day) 1.2 0.2 gamma Primary data
Monitoring cost
DAAs (12-week) 355.6 71.1 gamma Primary data
DAAs (24-week) 360.4 72.1 gamma Primary data
PegIFN1RBV (48-week) 525.3 105.1 gamma Primary data
Cost of palliative care (per year)
CHC 108.5 21.7 gamma Primary data
CC 598.7 119.7 gamma Primary data
DC 964.1 192.8 gamma Primary data
HCC 3,676.0 735.2 gamma Primary data
Direct non-medical cost (per year)
For antiviral treatment
CHC treated with DAAs 87.6 17.5 gamma Primary data
CC treated with DAAs 268.1 53.6 gamma Primary data
CHC/CC treated with PegIFN1RBV 235.7 47.1 gamma Primary data
For palliative care
CHC 174.1 34.8 gamma Primary data
CC 212.2 42.4 gamma Primary data
DC 364.5 72.9 gamma Primary data
HCC 334.2 66.8 gamma Primary data
Time cost (per year)
For antiviral treatment
CHC treated with DAAs 129.2 25.8 gamma Primary data
CC treated with DAAs 165.1 33.0 gamma Primary data
CHC treated with PegIFN1RBV 129.2 25.8 gamma Assumed
CC treated with PegIFN1RBV 165.1 33.0 gamma Assumed
For palliative care
CHC 189.8 38.0 gamma Primary data
CC 201.6 40.3 gamma Primary data
DC 369.9 74.0 gamma Primary data
continued on next page
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Table 1. Continued
Input parameters Mean Standard error Distribution Source
HCC 361.5 72.3 gamma Primary data
Utilities
CHC 0.878 0.026 triangular Primary data
CC 0.695 0.077 triangular Primary data
DC 0.491 0.155 triangular Primary data
HCC 0.358 0.160 triangular Primary data
Epidemiology
Genotype distribution in CHC-CC
population (target population)
Genotype 1 0.358 0.072 Beta 8
Genotype 6 0.642 0.128 Beta 8
CHC-CC distribution in genotype 1
CHC 0.550 0.110 Beta 9
CC 0.450 0.090 Beta 9
CHC-CC distribution in genotype 6
CHC 0.620 0.124 Beta 9
CC 0.380 0.076 Beta 9
CC indicates compensated cirrhosis; CHC, non-cirrhotic chronic hepatitis C; DAA, direct-acting antiviral; DC, decompensated cirrhosis; DCV, daclatasvir; HCC,
hepatocellular carcinoma; LDV, ledipasvir; LRD, liver-related death; PegIFN, pegylated-interferon; SOF, sofosbuvir; SVR12, sustained virologic response at 12th week
after treatment; RBV, ribavirin; VEL, velpatasvir.
-- 5multiplying the prevalent number of CHC and CC patients with
genotypes 1 and 61,8 with the current diagnosis rate,55 treatment
coverage,55 and proportion of eligible-to-treat population22
(Appendix Table 1 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2020.03.018). Consequently, the 5-year
affected population, given the annual discount rate of 3%, was
3711 persons.
Both pairwise EVPI (each DAA compared with PR) and general
EVPI (all DAAs and PR compared with each other) were estimated.
The EVPI was estimated by different ceiling ratios, whereas the
EVPPI used the ceiling ratios of 1 GDP per capita of Vietnam and
was run by 100 outer loops and 100 inner loops.Results
Model Validation
In addition to face validation performed by clinical experts, our
model’s predictions of HCV natural history were cross-validated
with other published modeling studies56-61 (Fig. S1B in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.03.
018). Regarding the cumulative incidence of CC (Fig. S1A), our
study predicted a 20-year cumulative incidence of 29.1%, which
was comparable with other studies,57-59,61 where this rate ranged
from 27.0% to 29.1%. In addition, the 10-year cumulative incidence
of DC, HCC, and LRD was predicted in our study, which were
15.5%, 18.1%, and 17.4%, respectively. However, in comparison to
the result of a multicenter follow-up study by van der Meer et al,56
our predicted rates were lower, and only the 10-year cumulative
incidence of HCC was within the reported confidence limits in van
der Meer’s study. These differences may be explained by the dif-
ferences in baseline population between models—our model
included HCV patients at mild to severe fibrosis stage, whereas in
van der Meer’s model, all patients were at severe fibrosis stage.56
Base-Case Analysis
The lifetime cumulative new cases of HCV-related complica-
tions (ie, DC, HCC, LRD) were projected in the model. Comparedwith PR, all DAA regimens were associated with lower cumulative
incidence of all complications. Specifically, DAA regimens
decreased the cumulative incidence of DC by 95.3% to 97.1%,
whereas the incidence of HCC and LRD was reduced by 23.5% to
23.9% and by 39.8% to 40.6%, respectively. In all cases, SOF/VEL
always resulted in the lowest incidence, thereby demonstrating
the highest effectiveness in terms of avoiding HCV-related com-
plications (Appendix Table 2 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.03.018).
The base-case cost-effectiveness analysis indicated that all
DAA regimens dominated PR (ie, were less costly and more
effective), based on both societal and payer perspectives (Table 2).
From a societal perspective, compared with PR, treatments with
DAA regimens in Vietnam’s HCV population genotypes 1 and 6
were associated with the increment of overall life expectancy by
0.65 to 0.66 years and the increment of discounted QALYs by 1.33
to 1.35 QALYs, whereas costs were significantly decreased by
$6519 to $7246. In addition, the lifetime costs of DAA regimens
and PR were further classified into intervention cost (ie, costs of
drugs and treatment monitoring) and non-intervention cost
(ie, costs of palliative care) and shown graphically, which
demonstrated the lower values of both intervention and non-
intervention costs of DAA regimens compared with PR (Fig. S2
in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2020.03.018).
Among 3 DAA regimens, SOF/VEL was associated with the
lowest lifetime cost at $4055 per patient and was found to be the
most efficacious at 15.09 QALYs. Furthermore, in order to directly
compare the cost-effectiveness among the 3 DAA regimens, the
corresponding NMB of all 3 DAA regimens was calculated, which
showed that SOF/VEL was the most cost-effective regimen, fol-
lowed by SOF/LDV as the second, and SOF1DCV as the third, from
both perspectives (Table 2).
Different scenarios of government’s co-payment rates (50%-
100%) were explored. In all scenarios, 3 DAAs remained cost-
saving in comparison to PR, and SOF/VEL remained the most
cost-effective regimen, regardless of the copayment rates, from
both perspectives (Appendix Table 3 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2020.03.018).
Table 2. Cost-effectiveness of direct-acting antivirals compared with pegylated-interferon plus ribavirin for treatment of chronic
hepatitis C virus genotypes 1 and 6 in Vietnam (US dollars, 2019).
Societal perspective PR SOF/LDV SOF/VEL SOF1DCV
Discounted cost 11 301 4430 4055 4782
Discounted LYs 14.69 15.34 15.36 15.35
Discounted QALYs 13.74 15.06 15.09 15.08
Incremental cost –6870 –7246 –6519
Incremental LYs 0.65 0.66 0.66
Incremental QALYs 1.33 1.35 1.34
ICER per LY Dominant Dominant Dominant
ICER per QALY Dominant Dominant Dominant
NMB* 21 519 31 555 31 993 31 234
Payer perspective PR SOF/LDV SOF/VEL SOF1DCV
Discounted cost 4611 2317 2101 2461
Discounted LYs 14.69 15.34 15.36 15.35
Discounted QALYs 13.74 15.06 15.09 15.08
Incremental cost –2294 –2509 –2149
Incremental LYs 0.65 0.66 0.66
Incremental QALYs 1.33 1.35 1.34
ICER per LY Dominant Dominant Dominant
ICER per QALY Dominant Dominant Dominant
NMB* 28 209 33 669 33 947 33 555
DAA indicates direct-acting antiviral; DCV, daclatasvir; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; LY, life-year; NMB, net
monetary benefit; PR, pegylated-interferon plus ribavirin; SOF, sofosbuvir; VEL, velpatasvir; QALY, quality-adjusted life-year
*At cost-effectiveness threshold of 1 GDP per capita in Vietnam: $2389 per QALY gained34
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One-way deterministic sensitivity analysis was shown graph-
ically as a tornado diagram (Fig. 2), which illustrated the param-
eters that most heavily influenced the incremental NMB (at the
cost-effectiveness threshold of 1 GDP per capita of Vietnam) of
the most cost-saving regimen (ie, SOF/VEL) compared to PR, from
a societal perspective. The incremental NMB was always positive,
which indicated that SOF/VEL always remained cost-effective at
the threshold of 1 GDP per capita of Vietnam. In addition, the
incremental NMB was most sensitive to the treatment efficacy of
PR and SOF/VEL, the discount rates for outcome and cost, the
distribution of HCV genotype 1 and 6 in Vietnam, and the utility
values. Furthermore, discount rates for costs at 3%, QALY at 1.5%,
and 1.5% for both QALY and costs were tested, which confirmed
the base-case results (Appendix Table 4 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2020.03.018).
The probabilistic sensitivity analysis, performed from a societal
perspective, confirmed the robustness of the base-case cost-
effectiveness result, of which all DAA regimens dominated PR, and
SOF/VEL was the most cost-saving regimen. Specifically, the
cost-effectiveness plane showed the cost-saving result of DAA
regimens in 100% of the 1000 simulations, whereas the
cost-effectiveness acceptability curve indicated that at all
willingness-to-pay thresholds, SOF/VEL always remained the most
cost-effective regimen (Fig. 3).Value of Information Analysis
The pairwise EVPI for population (each DAA regimen
compared to PR) was zero at all willingness-to-pay values (Fig. 4),
suggesting that the cost-saving results of any DAA regimen
compared to PR were robust and not likely to change even under
perfect information; therefore, further information might not be
necessary in this case.
The general EVPI for population (3 DAA regimens and PR
compared to each other) was $8.4 million at the willingness to pay
of 1 GDP per capita of Vietnam (Fig. 4), corresponding to an in-
dividual EVPI of $480. The difference between pairwise EVPI and
general EVPI implied that there were uncertainties among DAA
regimens (but not between any DAA regimen versus PR), which
were worthwhile to eliminate. As the willingness to pay increased,
the EVPI become higher owing to the increment of NMB; however,
no peak of EVPI curve could be observed, suggesting that the
current cost-effectiveness ranking among DAA regimens was
robust and not likely to change, even under the perfect
information.
The 5-year general EVPPI at the willingness to pay of 1 GDP per
capita of Vietnam was estimated on all major parameter groups,
including DAAs’ treatment efficacy, direct medical cost, direct non-
medical and time cost, transition probabilities, utilities, and
epidemiology (Fig. 4). The uncertainties were observed in DAA
efficacy and cost parameter groups, which suggested that if
Figure 2. Tornado diagram of sofosbuvir/velpatasvir compared with pegylated-interferon plus ribavirin for treatment of chronic
hepatitis C virus genotypes 1 and 6 in Vietnam from a societal perspective (US dollars, 2019).
CC indicates compensated cirrhosis; CHC, non-cirrhotic chronic hepatitis C; DAA, direct-acting antiviral; DC, decompensated cirrhosis; DCV, daclatasvir; GT,
genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LDV, ledipasvir; LRD, liver-related death; PegIFN, pegylated-interferon; PR, pegylated-
interferon 1 ribavirin; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response; RBV, ribavirin; VEL, velpatasvir.
-- 7further research is conducted, researchers should aim to obtain
better data on relative treatment efficacy between DAA regimens
or better cost estimation.Discussion
In this study, the cost-effectiveness of all available DAA regi-
mens in the Vietnamese health insurance drug list14 for HCV pa-
tients with genotypes 1 and 6 was assessed. All DAA regimens
were associated with lower cost and higher effectiveness, thereby
being cost-saving compared with PR, from both societal and payer
perspectives. Our results may be particularly useful for countries
with a high prevalence of HCV genotype 6, such as Laos (95.6%),
Cambodia (56.0%), Myanmar (49.0%), and Thailand (21.8%).12
The robustness of these findings was tested by performing
extensive deterministic and probabilistic sensitivity analyses,
which found that DAAs always remained cost-saving despite all
key parameters being varied across wide yet plausible ranges. The
most influential parameters were similar to those reported by
other modeling studies in the field.16
In addition, the result of EVPI for the population indicated a
small degree of uncertainty in the CUA results in all willingness-
to-pay scenarios, and the decision to adopt DAA regimens wouldnot be likely to change even under perfect information. Never-
theless, if policy makers demand more certain recommendation in
terms of cost-effectiveness ranking among DAA regimens, further
research to obtain better data on relative treatment efficacies
among DAA regimens or better cost estimation might be
worthwhile.
The cost-saving results of DAA regimens in Vietnam were
mainly attributed to the significantly lower DAA prices in Vietnam
compared with their original prices. The reduced prices were due
to the result of voluntary license agreements signed by the orig-
inator companies, which allowed HCV patients to access generic
DAAs. Currently, more than 100 countries around the world have
benefited from the license agreements, including a majority of
LMICs.62 Our study findings are in accordance with several studies
conducted in Asian countries, including a study of Rattanavipa-
pong63 in Thailand, where SOF/LDV and SOF1DCV regimens were
cost-saving compared with PR, and another study of Igarashi64 in
Japan, where SOF/LDV was also found to be cost-saving compared
with PR. Some other studies that compared DAA regimens to no
treatment also reported the cost-saving result of DAA regimens,
including a study of Aggarwal65 in India on SOF/LDV and
SOF1DCV, and another study of Goel66 in India on SOF/VEL.
To meet the World Health Organization’s goal of eliminating
HCV as a public health threat by 2030,67 a rapid scale-up of DAA
Figure 3. Probabilistic sensitivity analysis of DAAs compared with pegylated-interferon plus ribavirin for treatment of chronic hepatitis C
virus genotype 1 and 6 in Vietnam, under societal perspective (US dollars, 2019).
DAA indicates direct-acting antiviral; DCV, daclatasvir; GDP, gross domestic product; LDV, ledipasvir; PR, pegylated-interferon plus ribavirin; QALY, quality-
adjusted life-year; SOF, sofosbuvir; VEL, velpatasvir.
8 VALUE IN HEALTH - 2020treatment is required. Nevertheless, despite demonstrating the
cost-saving benefits for the society and payer in Vietnam, scale-up
of DAA treatment in reality might depend on other factors, such as
enabling financial accessibility for the HCV population, which isamong the most important factors. In a study by Thu Nguyen
et al68 that measured the willingness to pay of HCV patients for
diagnosis tests and 12-week antiviral treatment, 54.6% of patients
were not willing to pay more than $440. Meanwhile, our model
Figure 4. Value of information analysis (US dollars, 2019).
DAA indicates direct-acting antiviral; EVPI, expected value of perfect information; EVPPI, expected value of partial perfect information; GDP, gross domestic
product.
-- 9estimated that the total cost for diagnosis tests and the 12-week
DAA treatment was at least $980; in this case the DAA regimen
used was the cheapest one (ie, SOF/LDV), the patient had health
insurance (ie, the patient only needed to pay for 50% of DAA cost
and an average of 20% of testing cost), and the health state was
non-cirrhotic. Hence, the government should consider strategies
to reduce patients’ out-of-pocket payments for DAA treatment.
Several strategies might be considered, such as: (1) implementing
further price-reduction strategies; (2) increasing the government’s
copayment rate for DAA regimens, which currently is 50% (it
should be noted that, DAA regimens are still cost-saving at 100%
the government’s copayment rate, as demonstrated in the sce-
nario analysis); or (3) seeking donor support.
Limitations
This study has several limitations. First, our model assumed
that all patients complied with the treatment, although dropouts
were likely to occur in reality, which may overestimate the ben-
efits of DAA regimens. Second, we assumed that patients had no
comorbidities, but in reality, comorbidities may be common at 50
years old; therefore, we may underestimate the benefits of DAAregimens. Third, we did not consider the benefits of HCV treat-
ments in preventing transmissions in society; however, it is ex-
pected that the cost-effectiveness results of DAA regimens would
be more favorable if this public health benefit were taken into
account. Fourth, our model did not include liver transplantation as
a health state because it was neither included in the health in-
surance package nor currently widely accessible in Vietnam.
Lastly, owing to the unavailability of some epidemiological data in
Vietnam, such as annual age-specific incidence and prevalence of
HCV and its complications, in addition to the lack of longitudinal
studies on HCV patients, we cannot perform the model calibration
to fit actual data in the Vietnamese context. However, the results
of all uncertainty analyses have confirmed the robustness of our
cost-effectiveness results.
Conclusions
In conclusion, this study has demonstrated that all 3 DAA
regimens in the Vietnamese health insurance drug list (ie, SOF/
LDV, SOF1DCV, SOF/VEL) are cost-saving in HCV patients with
genotypes 1 and 6 from both societal and payer perspectives; thus,
10 VALUE IN HEALTH - 2020allocating resources for DAA treatment is surely a rewarding
public health investment. Our results may be particularly useful
for countries with a high prevalence of HCV genotype 6.
Furthermore, because more current evidence suggesting that
DAAs might be effective for advanced-stage HCV patients,69,70
future studies in LMICs should investigate the cost-utility of
DAAs among patients at all disease states.
In the DAAs era, the elimination of HCV as a public health
threat would be feasible, as illustrated by the evidence that we
have presented, yet this could not be accomplished without
seamless political commitments, a responsive health system, and
strong public support.Acknowledgments
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